Search Results - "Leonardi, Giulia C"

Ageing: from inflammation to cancer by Leonardi, Giulia C, Accardi, Giulia, Monastero, Roberto, Nicoletti, Ferdinando, Libra, Massimo

“…Ageing is the major risk factor for cancer development. Hallmark of the ageing process is represented by inflammaging, which is a chronic and systemic…”
Get full text

Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers by Cheong, Taek-Chin, Jang, Ahram, Wang, Qi, Leonardi, Giulia C., Ricciuti, Biagio, Alessi, Joao V., Di Federico, Alessandro, Awad, Mark M., Lehtinen, Maria K., Harris, Marian H., Chiarle, Roberto

“…Tyrosine kinase (TK) fusions are frequently found in cancers, either as initiating events or as a mechanism of resistance to targeted therapy. Partner genes…”
Get full text

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer by Bahcall, Magda, Awad, Mark M, Sholl, Lynette M, Wilson, Frederick H, Xu, Man, Wang, Stephen, Palakurthi, Sangeetha, Choi, Jihyun, Ivanova, Elena V, Leonardi, Giulia C, Ulrich, Bryan C, Paweletz, Cloud P, Kirschmeier, Paul T, Watanabe, Masayuki, Baba, Hideo, Nishino, Mizuki, Nagy, Rebecca J, Lanman, Richard B, Capelletti, Marzia, Chambers, Emily S, Redig, Amanda J, VanderLaan, Paul A, Costa, Daniel B, Imamura, Yu, Jänne, Pasi A

“…MET inhibitors can be effective therapies in patients with exon 14 ( ex14) mutant non-small cell lung cancer (NSCLC). However, long-term efficacy is limited by…”
Get full text

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders by Leonardi, Giulia C, Gainor, Justin F, Altan, Mehmet, Kravets, Sasha, Dahlberg, Suzanne E, Gedmintas, Lydia, Azimi, Roxana, Rizvi, Hira, Riess, Jonathan W, Hellmann, Matthew D, Awad, Mark M

“…Purpose Although programmed death (PD)-1 pathway inhibitors are now used in nearly all patients with advanced non-small-cell lung cancer (NSCLC), the large…”
Get full text

Cutaneous melanoma and the immunotherapy revolution (Review) by Leonardi, Giulia C, Candido, Saverio, Falzone, Luca, Spandidos, Demetrios A, Libra, Massimo

“…In a relatively short period of time, treatment strategies for metastatic melanoma have radically changed leading to an unprecedented improvement in patient…”
Get full text

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma by Skoulidis, Ferdinandos, Goldberg, Michael E, Greenawalt, Danielle M, Hellmann, Matthew D, Awad, Mark M, Gainor, Justin F, Schrock, Alexa B, Hartmaier, Ryan J, Trabucco, Sally E, Gay, Laurie, Ali, Siraj M, Elvin, Julia A, Singal, Gaurav, Ross, Jeffrey S, Fabrizio, David, Szabo, Peter M, Chang, Han, Sasson, Ariella, Srinivasan, Sujaya, Kirov, Stefan, Szustakowski, Joseph, Vitazka, Patrik, Edwards, Robin, Bufill, Jose A, Sharma, Neelesh, Ou, Sai-Hong I, Peled, Nir, Spigel, David R, Rizvi, Hira, Aguilar, Elizabeth Jimenez, Carter, Brett W, Erasmus, Jeremy, Halpenny, Darragh F, Plodkowski, Andrew J, Long, Niamh M, Nishino, Mizuki, Denning, Warren L, Galan-Cobo, Ana, Hamdi, Haifa, Hirz, Taghreed, Tong, Pan, Wang, Jing, Rodriguez-Canales, Jaime, Villalobos, Pamela A, Parra, Edwin R, Kalhor, Neda, Sholl, Lynette M, Sauter, Jennifer L, Jungbluth, Achim A, Mino-Kenudson, Mari, Azimi, Roxana, Elamin, Yasir Y, Zhang, Jianjun, Leonardi, Giulia C, Jiang, Fei, Wong, Kwok-Kin, Lee, J Jack, Papadimitrakopoulou, Vassiliki A, Wistuba, Ignacio I, Miller, Vincent A, Frampton, Garrett M, Wolchok, Jedd D, Shaw, Alice T, Jänne, Pasi A, Stephens, Philip J, Rudin, Charles M, Geese, William J, Albacker, Lee A, Heymach, John V

“…is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that (KL) or (KP) comutations define distinct subgroups of -mutant…”
Get more information

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease by Abu-Sbeih, Hamzah, Faleck, David M, Ricciuti, Biagio, Mendelsohn, Robin B, Naqash, Abdul R, Cohen, Justine V, Sellers, Maclean C, Balaji, Aanika, Ben-Betzalel, Guy, Hajir, Ibraheim, Zhang, Jiajia, Awad, Mark M, Leonardi, Giulia C, Johnson, Douglas B, Pinato, David J, Owen, Dwight H, Weiss, Sarah A, Lamberti, Giuseppe, Lythgoe, Mark P, Manuzzi, Lisa, Arnold, Christina, Qiao, Wei, Naidoo, Jarushka, Markel, Gal, Powell, Nick, Yeung, Sai-Ching J, Sharon, Elad, Dougan, Michael, Wang, Yinghong

“…The risk of immune checkpoint inhibitor therapy-related GI adverse events in patients with cancer and inflammatory bowel disease (IBD) has not been well…”
Get full text

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC by Recondo, Gonzalo, Bahcall, Magda, Spurr, Liam F, Che, Jianwei, Ricciuti, Biagio, Leonardi, Giulia C, Lo, Ying-Chun, Li, Yvonne Y, Lamberti, Giuseppe, Nguyen, Tom, Milan, Marina S D, Venkatraman, Deepti, Umeton, Renato, Paweletz, Cloud P, Albayrak, Adem, Cherniack, Andrew D, Price, Kristin S, Fairclough, Stephen R, Nishino, Mizuki, Sholl, Lynette M, Oxnard, Geoffrey R, Jänne, Pasi A, Awad, Mark M

“…Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKI) are poorly understood. We aimed to characterize the genomic mechanisms of…”
Get full text

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels by Ricciuti, Biagio, Wang, Xinan, Alessi, Joao V, Rizvi, Hira, Mahadevan, Navin R, Li, Yvonne Y, Polio, Andrew, Lindsay, James, Umeton, Renato, Sinha, Rileen, Vokes, Natalie I, Recondo, Gonzalo, Lamberti, Giuseppe, Lawrence, Marissa, Vaz, Victor R, Leonardi, Giulia C, Plodkowski, Andrew J, Gupta, Hersh, Cherniack, Andrew D, Tolstorukov, Michael Y, Sharma, Bijaya, Felt, Kristen D, Gainor, Justin F, Ravi, Arvind, Getz, Gad, Schalper, Kurt A, Henick, Brian, Forde, Patrick, Anagnostou, Valsamo, Jänne, Pasi A, Van Allen, Eliezer M, Nishino, Mizuki, Sholl, Lynette M, Christiani, David C, Lin, Xihong, Rodig, Scott J, Hellmann, Matthew D, Awad, Mark M

“…Although tumor mutation burden (TMB) has been explored as a potential biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus…”
Get more information

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis by Awad, Mark M., Leonardi, Giulia C., Kravets, Sasha, Dahlberg, Suzanne E., Drilon, Alexander, Noonan, Sinead A., Camidge, D. Ross, Ou, Sai-Hong I., Costa, Daniel B., Gadgeel, Shirish M., Steuer, Conor E., Forde, Patrick M., Zhu, Viola W., Fukuda, Yoko, Clark, Jeffrey W., Jänne, Pasi A., Mok, Tony, Sholl, Lynette M., Heist, Rebecca S.

“…•The impact of MET inhibition on survival in MET exon 14 mutant NSCLC is unclear.•Use of a MET inhibitor in METex14 NSCLC is associated with improved…”
Get full text

Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer by Ostios-Garcia, Lorena, Faig, Jennifer, Leonardi, Giulia C, Adeni, Anika E, Subegdjo, Safiya J, Lydon, Christine A, Rangachari, Deepa, Huberman, Mark S, Sehgal, Kartik, Shea, Meghan, VanderLaan, Paul A, Cheng, Matthew P, Marty, Francisco M, Hammond, Sarah P, Costa, Daniel B, Awad, Mark M

“…Despite widespread administration of programmed death receptor 1 (PD-1) pathway inhibitors among individuals with NSCLC, little is known about the safety and…”
Get more information

Emerging Biomarkers in the Era of Personalized Cancer Medicine by Ricciuti, Biagio, Leonardi, Giulia C., Brambilla, Marta

“…Huang and colleagues demonstrated that GRP94 silencing may increase the resistance of osteosarcoma cell lines (MG63 and 143B) to paclitaxel, gemcitabine, and…”
Get full text

Cutaneous melanoma: From pathogenesis to therapy (Review) by Leonardi, Giulia C, Falzone, Luca, Salemi, Rossella, Zanghì, Antonino, Spandidos, Demetrios A, Mccubrey, James A, Candido, Saverio, Libra, Massimo

“…In less than 10 years, melanoma treatment has been revolutionized with the approval of tyrosine kinase inhibitors and immune checkpoint inhibitors, which have…”
Get full text

Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer by Leonardi, Giulia C, Oxnard, Geoffrey R, Haas, Andrea, Lang, Joshua P, Williams, Jonathan S, Awad, Mark M

“…Programmed cell death protein 1 pathway inhibitors are now routinely administered to patients with non-small cell lung cancer, and prompt recognition of…”
Get full text

Abstract 2400: Strong biological bias for ALK intron 19 breakpoints in NSCLC by Leonardi, Giulia C., Cheong, Taek-Chin, Ambrogio, Chiara, Chen, Tao, Tai, Wei-Tien, Karaca, Elif, Mota, Ines, Libra, Massimo, Awad, Mark M., Blasco-Patino, Rafael, Chiarle, Roberto

“…Abstract Introduction: EML4-ALK translocations are detected in 4-8 % of non-small cell lung cancer (NSCLC). While different EML4-ALK variants are defined by…”
Get full text

Abstract 5305: DNA methylation and gene expression in melanoma: A large-scale integrated analysis by Candido, Saverio, Palumbo, Giuseppe A. Parasiliti, Russo, Giulia, Falzone, Luca, Leonardi, Giulia C., Pappalardo, Francesco, Libra, Massimo

“…Abstract Dysregulation of DNA methyltransferase activity, through global hypomethylation and localized hypermethylation phenomena, has been associated with…”
Get full text

Abstract 313: Mechanisms of oncogenic tyrosine kinase fusion formation and selection in human cancers by Cheong, Taek-Chin, Jang, Ahram, Wang, Qi, Leonardi, Giulia C., Lehtinen, Maria K., Harris, Marian H., Chiarle, Roberto

“…Abstract Introduction: Tyrosine kinase (TK) fusions are common events in the development of resistance to targeted therapy for non-small cell lung cancer…”
Get full text